Suppr超能文献

儿科肥大细胞增多症的临床方面:101 例回顾。

Clinical aspects of paediatric mastocytosis: a review of 101 cases.

机构信息

Department of Dermatology, Medical University of Gdansk Children's Hospital Polanki, Gdansk, Poland.

出版信息

J Eur Acad Dermatol Venereol. 2013 Jan;27(1):97-102. doi: 10.1111/j.1468-3083.2011.04365.x. Epub 2011 Nov 30.

Abstract

BACKGROUND

Cutaneous mastocytosis (CM) is a typical presentation of mastocytosis in children. However, systemic mastocytosis may also occur in children.

OBJECTIVE

We tried to characterize the clinical features of childhood-onset mastocytosis and estimate the value of the SCORMA (SCORing Mastocytosis) Index and serum tryptase levels as disease severity parameters.

METHODS

In a survey of 101 children mastocytosis was diagnosed and classified according to World Health Organization criteria. In all the cases serum tryptase levels and the SCORMA Index were done to assess the extent and intensity of the disease.

RESULTS

Cutaneous mastocytosis was diagnosed in 100 children; 84% of them presented maculopapular CM, 10% mastocytoma and 6% diffuse cutaneous mastocytosis. Moreover, systemic mastocytosis with bone marrow infiltration and associated with maculopapular CM was found in one case. There was a positive correlation of serum tryptase level to the SCORMA Index. Both the mean tryptase level and the mean SCORMA Index were elevated in diffuse cutaneous mastocytosis children when compared with other forms CM. A significantly higher mean tryptase level was found in children with flushing, hypotension, diarrhoea, extensive bullous lesions and osteoporosis or osteopenia.

CONCLUSION

Mastocytosis in children usually has a benign course. Nevertheless, severe mediator-related symptoms and systemic involvement may appear. Therefore, a multidisciplinary approach involving careful monitoring of the serum tryptase level, SCORMA Index and the organ function is recommended. Both tryptase levels and the SCORMA Index are of a great value as disease severity parameters and they should be assessed simultaneously in all mastocytosis patients.

摘要

背景

皮肤肥大细胞增多症(CM)是儿童肥大细胞增多症的典型表现。然而,系统性肥大细胞增多症也可能发生在儿童中。

目的

我们试图描述儿童肥大细胞增多症的临床特征,并评估 SCORMA(肥大细胞增多症评分)指数和血清胰蛋白酶水平作为疾病严重程度参数的价值。

方法

在对 101 例儿童肥大细胞增多症的调查中,根据世界卫生组织标准进行诊断和分类。在所有病例中,均进行血清胰蛋白酶水平和 SCORMA 指数检查,以评估疾病的范围和强度。

结果

诊断出 100 例皮肤肥大细胞增多症;其中 84%表现为斑丘疹 CM,10%为肥大细胞瘤,6%为弥漫性皮肤肥大细胞增多症。此外,在一例病例中发现了伴有斑丘疹 CM 的系统性肥大细胞增多症,伴有骨髓浸润。血清胰蛋白酶水平与 SCORMA 指数呈正相关。与其他形式的 CM 相比,弥漫性皮肤肥大细胞增多症患儿的平均胰蛋白酶水平和平均 SCORMA 指数均升高。在有潮红、低血压、腹泻、广泛水疱性病变和骨质疏松或骨量减少的患儿中,发现胰蛋白酶水平显著升高。

结论

儿童肥大细胞增多症通常具有良性病程。然而,可能会出现严重的介质相关症状和全身受累。因此,建议采用多学科方法,包括仔细监测血清胰蛋白酶水平、SCORMA 指数和器官功能。胰蛋白酶水平和 SCORMA 指数作为疾病严重程度参数具有重要价值,应在所有肥大细胞增多症患者中同时评估。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验